Diane E. Wilfong net worth and biography

Diane Wilfong Biography and Net Worth

CAO of Gilead Sciences

Ms. Diane E. Wilfong, CPA, is a Chief Accounting Officer & Senior Vice President at Gilead Sciences, Inc. and a Member at The American Institute of Certified Public Accountants. She is on the Board of Directors at Impel NeuroPharma, Inc. Ms. Wilfong was previously employed as a Chief Accounting Officer & Controller by Computer Sciences Corp., a Chief Accounting Officer, Senior VP & Controller by Caesars Entertainment Corp., a Chief Accounting Officer & Controller by Eastman Kodak Co., a Chief Financial Officer by Corning Asahi Video Products Co. /Certain Mftg Assets/, an Audit Manager by PricewaterhouseCoopers LLP, and a Chief Accounting Officer, Senior VP & Controller by Harrah's Entertainment, Inc. She also served on the board at CSRA, Inc. She received her undergraduate degree from Kenan-Flagler Business School.

What is Diane E. Wilfong's net worth?: The estimated net worth of Diane E. Wilfong is at least $2.62 million as of November 9th, 2022. Ms. Wilfong owns 28,333 shares of Gilead Sciences stock worth more than $2,622,786 as of December 21st. This net worth evaluation does not reflect any other assets that Ms. Wilfong may own. Learn More about Diane E. Wilfong's net worth.
How do I contact Diane E. Wilfong?: The corporate mailing address for Ms. Wilfong and other Gilead Sciences executives is 333 LAKESIDE DRIVE, FOSTER CITY CA, 94404. Gilead Sciences can also be reached via phone at (650) 574-3000 and via email at [email protected]. Learn More on Diane E. Wilfong's contact information.
Has Diane E. Wilfong been buying or selling shares of Gilead Sciences?: Diane E. Wilfong has not been actively trading shares of Gilead Sciences over the course of the past ninety days. Learn More on Diane E. Wilfong's trading history.
Who are Gilead Sciences' active insiders?: Gilead Sciences' insider roster includes Gregg Alton (EVP), Jeffrey Bluestone (Director), Paul Carter (EVP), John Cogan (Director), Andrew Dickinson (Exec. VP & CFO ), Andrew Dickinson (CFO), John Martin (Director), Johanna Mercier (Insider), James Meyers (EVP), John Milligan (Insider), Daniel O'Day (Chairman & CEO ), Merdad Parsey (Insider), Brett Pletcher (EVP), Javier Rodriguez (Director), Robin Washington (CFO), Richard Whitley (Director), and Diane Wilfong (CAO). Learn More on Gilead Sciences' active insiders.
Are insiders buying or selling shares of Gilead Sciences?: In the last year, insiders at the biopharmaceutical company sold shares 13 times. They sold a total of 509,823 shares worth more than $46,496,330.96. The most recent insider tranaction occured on December, 16th when CFO Andrew D Dickinson sold 8,500 shares worth more than $781,660.00. Insiders at Gilead Sciences own 0.2% of the company. Learn More about insider trades at Gilead Sciences.
Information on this page was last updated on 12/16/2024.

Diane E. Wilfong Insider Trading History at Gilead Sciences

Diane E. Wilfong Buying and Selling Activity at Gilead Sciences

Gilead Sciences Company Overview

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

Today's Range

Now: $92.57

$90.71

$93.29

50 Day Range

MA: $90.64

$85.05

$97.90

2 Week Range

Now: $92.57

$62.07

$98.90

Volume

22,529,402 shs

Average Volume

7,132,954 shs

Market Capitalization

$115.37 billion

P/E Ratio

1,028.56

Dividend Yield

3.40%

Beta

0.18

Did You See Trump’s Bombshell Exec. Order 001?

From Banyan Hill Publishing | Ad

Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."

I put all the details together for you here — but please hurry.